NCHR Comments on FDA’s Draft Guidance on Patient-Focused Drug Development

September 11, 2018. We support FDA’s efforts to increase patient engagement and input into medical product development and testing. However, we recognize how challenging it is to ensure that the information will reflect the views and experiences of a representative sample of patients. That challenge must be met in order to develop treatments that have a more meaningful impact on patients’ lives with risks that patients consider acceptable.

Read More »

NCHR Comments to EPA on Principles to Applying Systematic Review in TSCA Risk Evaluations

August 16, 2018. Protecting the public health requires that EPA’s draft guidance for applying a systematic review process for risk evaluations is scientifically valid, reliable, and accepted by the scientific community. It should consider the totality of the scientific evidence without often irrelevant or industry-centric requirements that would reduce the impact of high quality sources or exclude them.

Read More »

Letter to Members of Congress Opposing the “Accurate Labels Act”

July 11, 2018. We urge you to oppose this dangerous family-unfriendly legislation that: undermines the health of the American public; eliminates states’ existing ability to inform their citizens about the ingredients of products and the dangers that they may pose; and keeps Americans in the dark about the products they bring into their homes.

Read More »
Page 4 of 66« First...23456...102030...Last »